A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered with (EMR200064-001)Two Different Treatment Schedules in Subjects with Advanced Solid Tumors.

Trial Profile

A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered with (EMR200064-001)Two Different Treatment Schedules in Subjects with Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs MSC 2015103B (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors EMD Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 Status changed from completed to discontinued.
    • 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top